The effectiveness of controlled ovarian stimulation with tamoxifen for patients with estrogen‐sensitive breast cancer: A systematic review and meta‐analysis

The effectiveness of controlled ovarian stimulation with tamoxifen for patients with estrogen‐sensitive breast cancer: A systematic review and meta‐analysis

Abstract Purpose Tamoxifen is used for the suppression of estrogen‐sensitive tumor recurrence in oocyte retrieval cycles. This meta‐analysis aimed to evaluate the quality of controlled ovarian stimulation (COS) with co‐administration of gonadotropins and tamoxifen (COS with tamoxifen). Methods PubMe...

Full description

Bibliographic Details
Main Authors:	Tsukasa Yoshida, Osamu Takahashi, Yoko Suzuki, Erika Ota, Tetsuya Hirata
Format:	Article
Language:	English
Published:	Wiley 2023-01-01
Series:	Reproductive Medicine and Biology
Subjects:	aromatase inhibitors breast neoplasms fertility preservation reproductive techniques tamoxifen
Online Access:	https://doi.org/10.1002/rmb2.12543

Similar Items

The serum estradiol/oocyte ratio in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins
by: Yoo Jin Shim, et al.
Published: (2018-03-01)

Cutaneous sarcoidosis possibly associated with aromatase inhibitors and tamoxifen
by: Tomoya Sawada, MD, et al.
Published: (2023-06-01)

Tamoxifen decreases ovarian toxicity without compromising cancer treatment in a rat model of mammary cancer
by: Anna Nynca, et al.
Published: (2023-06-01)

Multidisciplinary Approach to Neoadjuvant Endocrine Therapy in Breast Cancer: A Comprehensive Review
by: Tomás Reinert, et al.
Published: (2016-12-01)

The effect of tamoxifen therapy on the endometrium and ovarian cyst formation in patients with breast cancer
by: Seul Lee, et al.
Published: (2018-09-01)

Effects of tamoxifen and aromatase inhibitors on the risk of acute coronary syndrome in elderly breast cancer patients: An analysis of nationwide data
by: Sung Hyouk Choi, et al.
Published: (2020-12-01)

Younger tamoxifen-treated breast cancer patients also had higher risk of endometrial cancer and the risk could be reduced by sequenced aromatase inhibitor use: A population-based study in Taiwan
by: Sung-Chao Chu, et al.
Published: (2020-01-01)

Anti-estrogen Treatment in Endometrial Cancer: A Systematic Review
by: Willem Jan van Weelden, et al.
Published: (2019-05-01)

Antiestrogen therapy in recurrent ovarian cancer resulting in 28 months of stable disease: A case report and review of the literature
by: Carter Jori, et al.
Published: (2010-01-01)

Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
by: Butani D, et al.
Published: (2021-11-01)

Dietary Supplement Use and Interactions with Tamoxifen and Aromatase Inhibitors in Breast Cancer Survivors Enrolled in Lifestyle Interventions
by: Maura Harrigan, et al.
Published: (2021-10-01)

A REPORT OF 4 CASES OF ASSISTED REPRODUCTION AFTER FERTILITY-SPARING SURGERY IN PATIENTS WITH BORDERLINE OVARIAN TUMORS AND LITERATURE REVIEW
by: GE Yanxin, LIU Hui, XIANG Yanjie
Published: (2023-10-01)

Random‐start ovarian stimulation with aromatase inhibitor for fertility preservation in women with Japanese breast cancer
by: Takashi Nakasuji, et al.
Published: (2019-04-01)

Systematic review of economic evaluations of aromatase inhibitors in estrogen receptor-positive breast cancer: quality evaluation
by: Maha F. Althuwaibi, et al.
Published: (2023-06-01)

Tamoxifen non-estrogen receptor mediated molecular targets
by: Tatiana Bogush, et al.
Published: (2012-10-01)

Adjuvant CMF and tamoxifen in the elderly breast cancer patients
by: Vrbavac Milenko, et al.
Published: (2002-01-01)

Study of Sperm Parameters and Sperm Fertility in Mice were Exposed to Tamoxifen during Embryonic Development
by: J Soleimanirad, et al.
Published: (2017-05-01)

Switching to anastrozole plus goserelin vs continued tamoxifen for adjuvant therapy of premenopausal early-stage breast cancer: preliminary results from a randomized trial
by: Li J, et al.
Published: (2018-12-01)

Bilateral ovarian endometriomas after laparoscopic hysterectomy following adjuvant tamoxifen therapy for breast cancer: A case report
by: Satoshi Nishiyama, et al.
Published: (2022-10-01)

Prospects for the use of selective estrogen receptor modulator tamoxifen
Published: (2012-03-01)

Maximize the safety and efficacy of fertility preservation by random start/dual ovarian stimulation for early breast cancer patients
by: Shih-Hung Richard Young, et al.
Published: (2023-03-01)

Oophorectomy in Premenopausal Patients with Estrogen Receptor-Positive Breast Cancer: New Insights into Long-Term Effects
by: Fatima Khan, et al.
Published: (2023-02-01)

Identification of influential factors on ovarian responsiveness with tamoxifen in type-2 WHO anovulatory patients
by: T. Madani, et al.
Published: (2005-01-01)

Adverse effects of adjuvant endocrine therapy
by: E. I. Kovalenko, et al.
Published: (2018-07-01)

Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction
by: Rakhshanda Layeequr Rahman, et al.
Published: (2012-10-01)

SYSTEMIC TREATMENT IN DUCTAL CARCINOMA IN SITU
by: Bülent Karagöz, et al.
Published: (2013-04-01)

CITED1 as a marker of favourable outcome in anti-endocrine treated, estrogen-receptor positive, lymph-node negative breast cancer
by: Malin Dahlgren, et al.
Published: (2023-06-01)

Use of antipsychotics with tamoxifen
by: H. Ghabi, et al.
Published: (2021-04-01)

Agonistic activity of tamoxifen, a selective estrogen-receptor modulator (SERM), on arthritic ovariectomized mice
by: L.A.S. Silva, et al.
Published: (2017-11-01)

The role of tamoxifen in the therapy of metastatic ovarian cancer
by: I S Davidenko, et al.
Published: (2014-03-01)

Increased Sclerostin Levels after Further Ablation of Remnant Estrogen by Aromatase Inhibitors
by: Wonjin Kim, et al.
Published: (2015-03-01)

Does the Time of Day at Which Endocrine Therapy Is Taken Affect Breast Cancer Patient Outcomes?
by: Ana-Alicia Beltran-Bless, et al.
Published: (2021-07-01)

Evaluation of Arthralgia Induced by Aromatase Inhibitor Therapy
by: Gulabi Mese, et al.
Published: (2013-02-01)

Risk of developing depression from endocrine treatment: A nationwide cohort study of women administered treatment for breast cancer in South Korea
by: Jooyoung Oh, et al.
Published: (2022-09-01)

Switching of Hormone Therapies in Breast Cancer Women
by: Luana Moreira de Medeiros, et al.
Published: (2021-05-01)

Effects of alcoholic extract of panax ginseng Seeds and Tamoxifen citrate drug on some fertility parameters and histopathological changes in testes of mice treated with doxorubicin
by: Huda F. Hasan
Published: (2016-06-01)

Repurposing of the Tamoxifen Metabolites to Combat Infections by Multidrug-Resistant Gram-Negative Bacilli
by: Andrea Miró-Canturri, et al.
Published: (2021-03-01)

Effect of Tamoxifen on the Risk of Osteoporosis and Osteoporotic Fracture in Younger Breast Cancer Survivors: A Nationwide Study
by: Jihyoun Lee, et al.
Published: (2020-03-01)

Bilateral Macular Edema in a Patient Treated with Tamoxifen: A Case Report and Review of the Literature
by: Paraskevas Zafeiropoulos, et al.
Published: (2014-12-01)

Risk of Endometrial Cancer and Frequencies of Invasive Endometrial Procedures in Young Breast Cancer Survivors Treated With Tamoxifen: A Nationwide Study
by: Soojeong Choi, et al.
Published: (2021-06-01)